Haleon PLC (HLN)
8.32
-0.03
(-0.36%)
USD |
NYSE |
May 02, 16:00
8.32
0.00 (0.00%)
After-Hours: 20:00
Haleon Enterprise Value: 48.89B for May 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 01, 2024 | 48.89B |
| April 30, 2024 | 49.71B |
| April 29, 2024 | 49.44B |
| April 26, 2024 | 49.35B |
| April 25, 2024 | 49.12B |
| April 24, 2024 | 48.89B |
| April 23, 2024 | 49.16B |
| April 22, 2024 | 48.93B |
| April 19, 2024 | 48.30B |
| April 18, 2024 | 47.88B |
| April 17, 2024 | 47.79B |
| April 16, 2024 | 47.75B |
| April 15, 2024 | 47.57B |
| April 12, 2024 | 47.34B |
| April 11, 2024 | 48.07B |
| April 10, 2024 | 48.07B |
| April 09, 2024 | 48.62B |
| April 08, 2024 | 48.30B |
| April 05, 2024 | 48.62B |
| April 04, 2024 | 48.34B |
| April 03, 2024 | 48.39B |
| April 02, 2024 | 48.57B |
| April 01, 2024 | 48.84B |
| March 28, 2024 | 49.53B |
| March 27, 2024 | 49.71B |
| Date | Value |
|---|---|
| March 26, 2024 | 49.16B |
| March 25, 2024 | 49.25B |
| March 22, 2024 | 49.03B |
| March 21, 2024 | 48.80B |
| March 20, 2024 | 48.81B |
| March 19, 2024 | 49.45B |
| March 18, 2024 | 48.25B |
| March 15, 2024 | 49.13B |
| March 14, 2024 | 48.76B |
| March 13, 2024 | 50.42B |
| March 12, 2024 | 50.75B |
| March 11, 2024 | 50.29B |
| March 08, 2024 | 50.61B |
| March 07, 2024 | 50.24B |
| March 06, 2024 | 49.22B |
| March 05, 2024 | 49.22B |
| March 04, 2024 | 49.13B |
| March 01, 2024 | 49.78B |
| February 29, 2024 | 50.29B |
| February 28, 2024 | 47.98B |
| February 27, 2024 | 48.81B |
| February 26, 2024 | 48.95B |
| February 23, 2024 | 49.59B |
| February 22, 2024 | 49.27B |
| February 21, 2024 | 49.22B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
36.78B
Minimum
Sep 02 2022
53.41B
Maximum
Apr 20 2023
47.64B
Average
49.14B
Median
Oct 31 2023
Enterprise Value Benchmarks
| GSK PLC | 101.32B |
| Pfizer Inc | 211.91B |
| AstraZeneca PLC | 262.25B |
| Verona Pharma PLC | 1.006B |
| Adaptimmune Therapeutics PLC | 149.25M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.726M |
| Revenue (Quarterly) | 3.435B |
| Total Expenses (Quarterly) | 3.099B |
| Gross Profit Margin (Quarterly) | 53.54% |
| Profit Margin (Quarterly) | -0.11% |
| Earnings Yield | 3.40% |
| Operating Earnings Yield | 8.61% |
| Normalized Earnings Yield | 3.401 |